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Relationship of the Chemokine,
CXCL12, to Effects of Dietary Fat on
Feeding-Related Behaviors and
Hypothalamic Neuropeptide Systems
Kinning Poon, Jessica R. Barson, Hui T. Ho and Sarah F. Leibowitz*
Laboratory of Behavioral Neurobiology, The Rockefeller University, New York, NY, USA
The intake of a high fat diet (HFD), in addition to stimulating orexigenic neuropeptides
in the hypothalamus while promoting overeating and reducing locomotor behavior,
is known to increase inflammatory mediators that modulate neuronal systems in the
brain. To understand the involvement of chemokines in the effects of a HFD, we
examined in rats whether HFD intake affects a specific chemokine, CXCL12, and its
receptors, CXCR4 and CXCR7, in the hypothalamus together with the neuropeptides
and whether CXCL12 itself acts similarly to a HFD in stimulating the neuropeptides
and altering ingestion and locomotor behavior. Compared to low-fat chow, a HFD for
5 days significantly increased the expression of CXCL12 and its receptors, in both the
paraventricular nucleus (PVN) where the neuropeptides enkephalin (ENK) and galanin
were also stimulated and the perifornical lateral hypothalamus (PFLH) where orexin (OX)
and melanin-concentrating hormone (MCH) were increased. In contrast, the HFD had
no impact on expression of CXCL12 or its receptors in the arcuate nucleus (ARC) where
the carbohydrate-related peptide, neuropeptide Y (NPY), was suppressed. Analysis of
protein levels revealed a similar stimulatory effect of a HFD on CXCL12 levels in the PVN
and PFLH, as well as in blood, and an increase in the number of CXCR4-positive cells
in the PVN. In the ARC, in contrast, levels of CXCL12 and number of CXCR4-positive
cells were too low to measure. When centrally administered, CXCL12 was found to have
similar effects to a HFD. Injection of CXCL12 into the third cerebral ventricle immediately
anterior to the hypothalamus significantly stimulated the ingestion of a HFD, reduced
novelty-induced locomotor activity, and increased expression of ENK in the PVN where
the CXCR4 receptors were dense. It had no impact, however, on NPY in the ARC or
on OX and MCH in the PFLH where the CXCR4 receptors were not detected. These
results, showing CXCL12 in the hypothalamus to be stimulated by a HFD and to mimic
the effects of the HFD where its receptors are located, suggest that this chemokine
system may have a role in mediating both the neuronal and behavioral effects induced
by a fat-rich diet.
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INTRODUCTION
The intake of a diet rich in fat has been associated with a higher
prevalence of obesity (Bray et al., 1981; Flatt, 1988), which is
accompanied by behavioral changes including an increase in
ingestive behavior (Warwick et al., 2003; Chang et al., 2004) and
a reduction in spontaneous, overall locomotor activity (Barzel
et al., 2015; Wong et al., 2015). Studies in the hypothalamus, a
brain region involved in controlling food intake, energy balance,
and related behaviors, have identified in animals a variety of
orexigenic neuropeptides which mediate these behaviors affected
by a fat-rich diet. These neuropeptides include enkephalin
(ENK) and galanin (GAL) in the hypothalamic paraventricular
nucleus (PVN) and also orexin (OX) and melanin-concentrating
hormone (MCH) in the perifornical lateral hypothalamus
(PFLH). In adult animals, central injection of these neuropeptides
or their analogs stimulates preferential intake of a high-fat diet
(HFD) (Robert et al., 1989; Kyrkouli et al., 1990a,b; Gomori et al.,
2003; Naleid et al., 2007), and HFD intake in turn increases the
expression and levels of these orexigenic neuropeptides in the
PVN and PFLH (Akabayashi et al., 1994; Elliott et al., 2004;
Chang et al., 2007; Gaysinskaya et al., 2007), suggesting that
they function within a positive feedback circuit to promote
excess consumption. Administration of these neuropeptides also
induces changes in locomotor behavior, with subcutaneous or
intracerebral injection of an ENK analog found to depress
locomotor activity (Bhargava, 1978; Szekely et al., 1980), similar
to an effect produced by the consumption of a HFD (Novak
et al., 2010; Wong et al., 2015). This positive relationship
of these neuropeptides in the PVN and PFLH to dietary fat
is very different from that seen in the hypothalamic arcuate
nucleus (ARC), where another orexigenic peptide, neuropeptide
Y (NPY), is reduced by intake of a HFD and positively
associated with ingestion of a carbohydrate-rich diet (Stanley
et al., 1985; Jhanwar-Uniyal et al., 1993; Brown et al., 1998).
This evidence, closely relating these orexigenic peptides to dietary
macronutrients, lead us to question the molecular and cellular
mechanisms that may mediate the effects of a HFD on these
neuropeptide systems and subsequently on the ingestive and
locomotor behaviors they control.
Recent studies have brought attention to neuroinflammatory
systems, which affect neurochemical processes and various
behaviors. Spontaneous HFD consumption and dietary obesity
are often associated with a state of systemic low-grade
inflammation, which is known to affect the functioning of
peripheral organs (Milanski et al., 2009; Takanabe-Mori et al.,
2010) and may also influence the brain. The ingestion of a HFD
similar to dietary obesity can induce inflammation in both the
peripheral and the central nervous system, which is associated
with an increase in the production of neuroimmune factors such
as the cytokines, interleukin 1-beta and tumor necrosis factor-
alpha, and a superfamily of small proteins called the chemotactic
cytokines, also known as chemokines (Barbarroja et al., 2010;
Gregor and Hotamisligil, 2011). While chemokines have been
suggested to play an important role in systemic obesity (Rull et al.,
2010; Gregor and Hotamisligil, 2011), their function specifically
in the neural control of consummatory and related behaviors has
not been well characterized. There is one particular chemokine,
(C-X-C motif) ligand 12 (CXCL12), which has diverse effects
on the function of different neuronal cell types in the brain.
Specifically, CXCL12 is shown to promote the migration of
dopaminergic neurons in the midbrain (Wu et al., 2009; Wang
et al., 2011) and modulate electrical excitability of neurons in
the hypothalamus (Guyon et al., 2005b; Callewaere et al., 2006;
Guyon et al., 2006). This evidence, together with the finding
that HFD intake increases the levels of CXCL12 in circulating
immune cells (Fenton et al., 2009), hints at the possibility that
this chemokine may be involved in the effects of a HFD on brain
neuropeptides and certain behaviors.
To test this possibility, the present report examined and
compared the effects of a HFD to those of central CXCL12
administration on the CXCL12 and neuropeptide systems in the
hypothalamus and on the consumption of a HFD and related
behaviors. Specifically, using both molecular and behavioral
measures, this study tested whether: (1) endogenous gene
expression of CXCL12 and its receptors, CXCR4 or CXCR7,
is stimulated by HFD intake, in the same hypothalamic nuclei
where the orexigenic neuropeptides are also increased by
dietary fat; (2) protein levels of CXCL12 and its receptors are
similarly stimulated by HFD intake; (3) central administration
of CXCL12, like consumption of a HFD, increases caloric intake
and reduces novelty-induced locomotor activity; and (4) central
CXCL12 injection also stimulates the expression of orexigenic
neuropeptides believed to mediate these behaviors.
MATERIALS AND METHODS
Animals
Five groups (Figure 1) of adult, male Sprague–Dawley rats
(N = 82), weighing between 250 and 300 g at the start of all
FIGURE 1 | Schematic of methods. Four groups of rats were given either
chow or HFD (n = 16/group) and measurements were taken of locomotor
activity, HFD intake, and neuropeptide expression, and immunofluorescence
histochemistry was performed. A additional group of rats was cannulated
(n = 18) and given intracerebral injections of either saline or CXCL12, and
measurements were taken of locomotor activity, HFD intake, and
neuropeptide expression.
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experiments (Charles River Breeding Labs, Kingston, NY, USA),
were individually housed (22◦C, with lights off at 9:00 a.m.
for 12 h) in a fully accredited American Association for the
Accreditation of Laboratory Animal Care facility, according to
institutionally approved protocols as specified in the National
Institutes of Health Guide to the Care and Use of Animals and
also with the approval of the Rockefeller University Animal Care
and Use Committee. All animals were given 1 week to acclimate
to lab conditions, during which time they were maintained ad
libitum on low-fat laboratory chow (PicoLab Rodent Diet 20
5053, Lab Diet, St. Louis, MO, USA; 12% fat, 60% carbohydrate,
and 28% protein) and filtered water. All efforts were made to
minimize the use and suffering of animals. The first four groups
of rats (N = 64, n = 16 per group) were used in the HFD
experiments, while the fifth group (N = 18, n = 9 per group)
was used in a within-subject design to test the effects of CXCL12
injection, first on novelty-induced locomotor activity, then on
acute HFD intake, and finally, on neuropeptide expression.
Diet
For the experimental period, unless otherwise stated, rats were
maintained ad libitum on standard rodent chow (12% fat, 3.3
kcal/g). For the four groups of rats tested with HFD or chow
(n = 8/diet group), the HFD groups were acclimated for 3 days
prior to HFD testing with a 15 kcal pellet of the HFD in addition
to their regular chow. With the chow then removed, they were
given 5 days of 24-hr access to a HFD alone, while the chow
groups were given only the laboratory chow diet. This short-term
HFD regimen was used to examine the effects of the diet itself
while minimizing any changes in metabolism and body weight
produced by long-term consumption of a HFD. For the fifth
group of rats used in the CXCL12 injection experiments, both
HFD and chow were available during intake testing, with the
rats exhibiting a strong propensity to eat the HFD over chow.
The HFD diet consisted of 50% fat (5.15 kcal/g), as described
in our previous publications (Dourmashkin et al., 2006). It had
50% fat composed of 75% lard (Armor Star, Peoria, IL, USA) and
25% vegetable oil (Crisco, Orrville, OH, USA), 25% carbohydrate
from 30% dextrin (ICN Pharmaceuticals, Costa Mesa, CA, USA),
30% cornstarch (ICN Pharmaceuticals, Costa Mesa, CA, USA),
and 40% sucrose (Domino Foods Inc., Yonkers, NY, USA), and
25% protein from casein (Bio-Serv, Frenchtown, NJ, USA). It was
supplemented with minerals (USP XIV Salt Mixture Briggs; ICN
Pharmaceuticals, Costa Mesa, CA, USA) and vitamins (Vitamin
Diet Fortification Mixture; ICN Pharmaceuticals, Costa Mesa,
CA, USA). This diet is nutritionally complete and does not have
any detrimental effects on the health of the animals. It was stored
at 4◦C until use. Caloric intake and body weight were recorded
daily.
Brain Dissections
Rats were sacrificed by rapid decapitation, after 5 days of HFD
or chow access in the first and second groups or one hr after
CXCL12 injection in the fifth group. All food was removed 1 hr
prior to sacrifice. For the microdissections, the brain immediately
after sacrifice was placed in a matrix slicing guide with the ventral
surface facing up. Four 1.0 mm coronal cuts were made, with
the anterior middle optic chiasm (Bregma −1.3 mm) as the
anterior boundary (Paxinos and Watson, 2005). The second cut
was made 1.0 mm caudal to this, yielding a slice (Bregma −1.3
to −2.3 mm) that was used for microdissection of the PVN. The
third cut was made 1.0 mm caudal to the prior cut, yielding
a slice (Bregma −2.3 to −3.3 mm) used for microdissection
of the PFLH and ARC. These sections were placed on a glass
slide and rapidly dissected under a microscope. The PVN was
dissected as a reversed isosceles triangle, 1.0 mm bilateral to
the third ventricle and between the fornix structures. The PFLH
was taken bilaterally from the area surrounding each fornix,
with a target range of 0.2 mm medial and ventral to the fornix,
0.3 mm dorsal, and 0.4 mm lateral. The ARC was dissected as an
isosceles triangle dorsal to the median eminence, 0.5 mm bilateral
to the third ventricle. These dissections were either stored in
RNAlater (Sigma–Aldrich) for mRNA extraction or flash frozen
in isopentane for protein extraction.
Quantitative Real-Time Polymerase
Chain Reaction (qRT-PCR)
Neuropeptide and chemokine expression was examined at the
same time that neuropeptide changes have been previously
detected (Chang et al., 2007; Gaysinskaya et al., 2007), from the
first and fifth group using qRT-PCR in different, microdissected
brain regions. The mRNA from each microdissected sample
was purified using a Qiagen RNeasy kit (Qiagen, Valencia,
CA, USA), cDNA was synthesized using high capacity RNA-
to-cDNA master mix (Life Technologies, Grand Island, NY,
USA), and the SYBR Green PCR core reagents kit (Life
Technologies, Grand Island, NY, USA) was used for qRT-
PCR and was performed in MicroAmp Optic 96-well Reaction
Plates (Life Technologies, Grand Island, NY, USA) under the
condition of 2 min at 50◦C, 10 min at 95◦C, and 40 cycles
of 15 s at 95◦C and 1 min at 60◦C, as previously described
(Poon et al., 2012). The levels of target gene expression were
quantified relative to the level of cyclophilin-A, using the relative
quantification method. Primers were designed with the NCBI
Primer design tool (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/) to span an exon-exon gap to eliminate amplification of
genomic DNA. The primers used were: CXCL12 forward: 5′-
AGTGACGGTAAGCCAGTCAGCCT-3′, reverse: 5′-TGACGT
TGGCTCTGGCGACA-3′; CXCR4 forward: 5′-GGGCTGGAGA
GCGAGCATTGC-3′, reverse: 5′-AAGCAGGGTTCCTTGTT
GGAGTCA-3′; CXCR7 forward: 5′-GCCGCGAGGTCACTT
GGTTG-3′, reverse: 5′-CAGGGCCAGTTGATGTCCGAGTA-
3′. The primers for ENK, GAL, ENK, OX, MCH, NPY, and
CYC were designed as previously described (Chang et al., 2004).
The specificities of PCR products were confirmed by a single
band of corresponding molecular weight revealed by agarose
gel electrophoresis. The concentration of all target primers was
100 nM, and the CYC primer was 200 nM.
ELISA
Trunk blood and dissected brain regions were collected from
the second group of rats, and protein levels of CXCL12 were
measured via ELISA. Tissue was lysed in RIPA lysis buffer (Santa
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Cruz Biotechnology, Santa Cruz, CA, USA) and homogenized
manually using a mortar and pestle. A Lowry assay was
performed to determine the total protein in each sample, and
afterward, the homogenate was concentrated using a protein
concentrator (Millipore, Billerica, MA, USA). A mouse CXCL12
ELISA kit (R&D Systems, Minneapolis, MN, USA) was used
to measure levels of hypothalamic CXCL12 and performed
according to the manufacturer’s instructions. A total of 0.5 µg of
protein was loaded into each well. Protein levels of CXCL12 were
calculated relative to the standard curve of the standard samples.
Immunohistochemistry
Rats in the third group, after being given access for 5 days to
a HFD or chow diet, were deeply anesthetized with 20 mg/kg
xylazine (LLOYD Incorporated, Shenandoah, IA, USA) and
100 mg/kg ketamine (Fort Dodge Animal Health, Overland Park,
KS, USA) (i.p.). They were perfused transcardially with 0.9%
NaCl and then 4% paraformaldehyde, as previously described
(Barson et al., 2015). Brains were removed, post-fixed in 4%
paraformaldehyde for 24 h, transferred to 25% sucrose for 4 days
at 4◦C, and then frozen at−80◦C. Coronal brain slices containing
the different regions of the hypothalamus were processed for
CXCR4 immunohistochemistry, using a 1:200 dilution of rabbit
anti-CXCR4 (Abcam, Cambridge, MA, USA) and a 1:400 dilution
of Alexafluor secondary antibody, goat anti-rabbit 594 (Life
Technologies, Grand Island, NY, USA). Several antibodies for
CXCR7 were tested but did not label properly, suggesting a lack of
effective commercially available antibodies for CXCR7. Although
protein levels of CXCR7 could not be measured, the existence
of high levels of CXCR7 mRNA suggests a possibility that this
receptor may be present in these brain regions as shown in
transgenic mice (Banisadr et al., 2003).
Cannulations
Rats in the fifth group were anesthetized with ketamine
(75 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.) and supplemented
with ketamine when necessary. Stainless steel 21-gage guide
shafts (10 mm in length) were implanted in the following
coordinates: Posterior: −3.1 mm, Lateral: 0.0 mm, Ventral:
−6.0 mm, with reference to bregma, the midsaggital sinus, and
the level skull surface. Stainless steel stylets were left in the
guide shafts between injections to prevent occlusion. All animals
had 1 week to recover before testing, during which time they
were handled daily and their stylet was removed and replaced to
acclimate them to the injection procedure.
Microinjections
For the fifth group of rats, CXCL12 was delivered through 26-
gage stainless steel microinjectors with fused-silica tubing inside
(74 µm ID, 154 µm OD, Polymicro Technologies, Phoenix, AZ,
USA) that protruded 3 mm beyond the guide shaft to reach the
third cerebral ventricle (icv; Ventral −9.0 mm), where injections
could reach the hypothalamic nuclei. The CXCL12 (Prospec-
Tany Technogene Ltd, Ness-Ziona, Israel) was dissolved in
preservative-free 0.9% saline solution (Hospira Inc., Lake Forest,
IL, USA) immediately prior to microinjection, to achieve a
final concentration of 50 ng/3 µL, a dose used in other studies
to activate other neurochemical systems in the brain and also
alter locomotor behavior (Skrzydelski et al., 2007; Trecki and
Unterwald, 2009). Injections across the experiments, which
measured HFD intake, novelty-induced locomotor activity, and
neuropeptide expression, were balanced so that each rat received
injections of vehicle or 50 ng CXCL12 at least one time but
never twice in a row. Injections were given 3 h into the dark
cycle, immediately prior to behavioral testing. A syringe pump
delivered 3 µL during 60 s, and microinjectors were left in place
for an additional 60 s to allow for diffusion, after which rats were
placed in the locomotor activity chamber or in their home cage
where they were given a HFD. At least 4 days elapsed between
injections to allow for recovery.
Histological Analysis
To precisely verify the sites of microinjections, three rats were
injected with methylene blue dye and then were sacrificed by
rapid decapitation. Their brains were fixed and sliced on an
electronic microtome cryostat at −25◦C as 30 µm coronal
sections and examined microscopically. Methylene blue was
found at a 3 mm radial spread from the injection site (Figure 2).
For all rats used in the experiment, verification of the injection
sites was performed visually during their brain dissections.
Behavioral Testing
Rats in the fifth group that were not exposed to any stimuli and
were maintained on chow were tested 3 h into the dark cycle for
the effects of CXCL12 injection on novelty-induced locomotor
activity during first exposure. They were injected in a between-
subject design with 50 ng CXCL12 or with saline and were
moved 10 min later from the vivarium to a sound-attenuated
room and placed in a 17.0′′ × 17.0′′ (43.2 cm × 43.2 cm) open
field activity test chamber for 15 min (Med Associates, Inc., St.
Albans, VT, USA). For comparison with the effects of CXCL12
injection, the rats in the fourth group that were maintained for
5 days on a HFD or chow were given a similar 15-min test in the
open field activity chamber. In both groups, ambulatory episodes,
ambulatory distance, ambulatory time, and ambulatory counts,
which were quantified as the number of infrared beam breaks,
were recorded automatically during this 15-min period. Next, to
test the effects of CXCL12 on HFD intake, the same rats were first
trained to consume a HFD by being given a small, 15-kcal meal
of this diet daily for 3 days, with chow also available. Three hours
into the dark cycle, the rats were then injected in a within-subject
design with 50 ng CXCL12 or with saline, and their intake of HFD
was measured at 1, 3, and 24 h after injection.
Data Analysis
Differences between the effects of CXCL12 at multiple time-
points were assessed using a two-way repeated-measures
ANOVA, with time as a repeated measures followed up by a
one-way ANOVA for each time and then paired, two-tailed
t-tests when appropriate. Differences between HFD intake were
assessed using two-tailed t-tests. A one-way ANOVA was used in
experiments examining gene expression, followed by Bonferroni’s
post hoc test when appropriate. Significance was determined at
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FIGURE 2 | Histological analysis. To verify the sites of microinjections, methylene blue was injected into three rats, and the brains were sliced as 30 µm coronal
sections. Methylene blue was detected at a 3 mm radial spread from the injection site. (Left) diagram of coronal section at −3.12 mm from bregma;© cannulation
site, D injection site. (Right) photomicrographs showing cannula placement in the three rats.
p< 0.05. Data are reported as mean± standard error of the mean
(SEM).
RESULTS
HFD Intake Increases mRNA Expression
of CXCL12 and its Receptors
With dietary fat known to induce inflammation and stimulate
fat-related neuropeptides, this experiment tested whether HFD
intake affects endogenous expression of CXCL12 and its
receptors, CXCR4 and CXCR7, in the same hypothalamic regions
where it affects the orexigenic neuropeptides. Rats consuming the
HFD for 5 days compared to those consuming a low-fat chow diet
exhibited a significant increase in daily caloric intake (Figure 3A)
and body weight (Figure 3B). In addition, consumption of the
HFD significantly increased serum levels of CXCL12 [+13%;
t(10) = 3.15, p < 0.05] (Figure 3C). Consistent with prior
studies (Dourmashkin et al., 2006), this short-term HFD regimen
also had a significant main effect on gene expression across
brain areas [F(1,4) = 140.47, p < 0.001] and a significant
diet × gene expression interaction effect [F(1,16) = 81.52,
p< 0.001] (Figure 4). In the PVN, measurements of mRNA levels
revealed both a main effect of HFD [F(1,10)= 1293.50, p< 0.001]
and an interaction effect between diet × gene expression
[F(4,20) = 126.80, p < 0.001]. These effects in the PVN reflected
a significant, HFD-induced increase in the expression of CXCL12
[t(10) = 4.27, p < 0.01], CXCR4 [t(10) = 5.11, p < 0.001],
and CXCR7 [t(10) = 4.21, p < 0.01], which was accompanied
by an increase in mRNA levels of the orexigenic neuropeptides,
ENK [t(10) = 2.93, p < 0.05] and GAL [t(10) = 3.36, p < 0.01]
(Figure 4A). In the PFLH, a main effect of diet [F(1,10)= 140.30,
p < 0.001] and an interaction effect between diet × gene
expression [F(4,20) = 99.65, p < 0.001] were also observed,
with the HFD significantly increasing the expression of CXCL12
[t(10) = 4.01, p < 0.01], CXCR4 [t(10) = 6.39, p < 0.001],
and CXCR7 [t(10) = 3.09, p < 0.05] in association with a
significant increase in expression of the orexigenic peptides, OX
[t(10) = 4.11, p < 0.01] and MCH [t(10) = 4.08, p < 0.01]
(Figure 4B). Whereas a main effect of diet [F(1,10) = 26.30,
p < 0.01)] and an interaction effect between diet × gene
expression [F(4,15) = 12.60, p < 0.001] were also observed in
the ARC, these effects reflected a very different pattern of change
from that seen in the PVN and PFLH. In the ARC, the HFD had
no impact on the expression of CXCL12 [t(10)= 0.45, p= 0.66],
CXCR4 [t(10) = 1.22, p = 0.25], or CXCR7 [t(10) = 0.35,
p = 0.73] and caused a significant decrease in expression of
NPY [t(10) = 2.41, p < 0.05] (Figure 4C). These results provide
anatomical evidence closely linking changes in the CXCL12
chemokine system to those in the orexigenic neuropeptide
Frontiers in Behavioral Neuroscience | www.frontiersin.org 5 March 2016 | Volume 10 | Article 51
fnbeh-10-00051 March 18, 2016 Time: 18:19 # 6
Poon et al. CXCL12, HFD, Behaviors and Neuropeptides
FIGURE 3 | Effects of high-fat diet on caloric intake, body weight and CXCL12. Ingestion of a HFD for 5 days significantly increased: (A) daily caloric intake,
(B) body weight, and (C) blood levels of CXCL12, as compared to rats ingesting low-fat chow diet. N = 16, ‡p < 0.001.
FIGURE 4 | Effects of high-fat diet on chemokine and neuropeptide expression. Ingestion of a HFD for 5 days: (A) increased the expression of endogenous
CXCL12 and its receptors, CXCR4 and CXCR7, in the hypothalamic paraventricular nucleus (PVN), as well as expression of the orexigenic neuropeptides,
encephalin (ENK) and galanin (GAL); (B) increased the expression of CXCL12 and its receptors in the perifornical lateral hypothalamus (PFLH), as well as expression
of the orexigenic neuropeptides, orexin (OX) and melanin-concentrating hormone (MCH); and (C) had no effect on CXCL12, CXCR4, or CXCR7 mRNA levels in the
arcuate nucleus (ARC), where it reduced expression of the orexigenic, neuropeptide Y (NPY). N = 16, †p < 0.05, ∗p < 0.01, ‡p < 0.001.
systems, with HFD intake stimulating CXCL12 and its receptors
in the PVN and PFLH where the fat-related neuropeptides are
similarly increased and having no impact on this chemokine
or its receptors in the ARC where the carbohydrate-related
neuropeptide is suppressed by the HFD.
HFD Intake Increases Protein Levels of
CXCL12 and CXCR4
With the HFD found to increase mRNA expression of CXCL12
and its receptors in the hypothalamus, this experiment measured
whether their protein levels are similarly affected by this diet.
Measurements of CXCL12 protein levels in the PVN, PFLH and
ARC were performed using an ELISA. The HFD compared to
chow diet induced a significant increase in CXCL12 levels in
the PVN [+20%; t(14) = 2.58, p < 0.05] and PFLH [+24%;
t(14) = 2.99, p < 0.01] (Figure 5A), while the level of CXCL12
in the ARC was too low to measure. Further analyses of
immunofluorescence labeling of CXCR4-positive cells revealed
a significant, HFD-induced increase in the density of CXCR4
neurons in the PVN [t(8) = 3.08, p < 0.05] (Figure 5B), as
illustrated in the photomicrographs (Figures 5C,D). This is
in contrast to the ARC as well as the PFLH, where CXCR4-
immunoreactive cells were not detected in either the chow or
HFD groups. These results show that a HFD increases protein
levels, similar to mRNA levels, of CXCL12 and CXCR4 in a site-
specific manner, with the PVN showing the strongest and most
consistent effect, the PFLH exhibiting a change in CXCL12 but
lacking the CXCR4 receptor, and the ARC having undetectable
levels of both CXCL12 and CXCR4 under chow and HFD
conditions.
Central Injection of CXCL12 Affects HFD
Intake
With a HFD generally known to be overconsumed as shown in
the first experiment and also found here to stimulate the CXCL12
receptor system, we tested in this next experiment the possibility
that central administration of CXCL12 itself compared to saline
vehicle acts similarly to a HFD in stimulating caloric intake.
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FIGURE 5 | Effects of high-fat diet on protein levels of CXCL12 and CXCR4. (A) Ingestion of a HFD for 5 days significantly increased the levels of CXCL12 in
both the PVN and PFLH, as compared to rats ingesting low-fat chow diet. N = 16. (B) Ingestion of a HFD for 5 days significantly increased the number of
CXCR4-immunoreactive cells in the PVN, as compared to low-fat chow diet. (C) Representative photomicrograph of CXCR4-immunoreactive cells as illustrated in
PVN from chow rats; and (D) HFD rats. N = 16, †p < 0.05, ∗p < 0.01.
This chemokine was injected into the third cerebral ventricle
at a dose (50 ng/3 µL) found in other studies to activate other
neurochemical systems in the brain and also to alter locomotor
behavior (Skrzydelski et al., 2007; Trecki and Unterwald, 2009).
At this dose, CXCL12 injection produced a significant change in
the intake of a HFD [F(1,26) = 1351.87, p < 0.001]. This change
reflected an increase in caloric intake, which was evident at both
1 h [t(52) = 2.89, p < 0.01] and 3 h [t(52) = 2.57, p < 0.05]
post-injection but not at 24 h [t(52) = 1.18, p = 0.24], indicating
that ingestive behavior had returned to normal levels (Figure 6).
While both chow and HFD were present post-injection, the rats
solely ate the HFD and not the chow. These results reveal an acute
stimulatory effect of CXCL12 itself on HFD intake, suggesting
this chemokine may control ingestive behavior.
Central CXCL12 Injection Is Similar to a
HFD in Affecting Novelty-Induced
Locomotor Activity
With CXCL12 found to mimic the stimulatory effect of a
HFD on caloric intake and a HFD also known to reduce
locomotor behavior (see Introduction), this experiment further
tested whether CXCL12 acts similarly to a HFD in affecting
novelty-induced locomotor activity in an open field. After 5 days
of ingesting HFD compared to chow, measures of locomotor
activity, defined as ambulatory episodes, ambulatory distance,
ambulatory time, and ambulatory counts, were recorded for
FIGURE 6 | Effects of CXCL12 on high-fat diet intake. Injection of
CXCL12 into the third ventricle induced a significant increase in HFD intake
over the first 3 h post-injection. N = 16, †p < 0.05, ∗p < 0.01.
15 min in a novel open field. Analyses of these measures over
the full 15 min revealed a significant, main effect of HFD on
locomotor activity [F(1,56) = 33.20, p < 0.001] (Supplementary
Table S1). This reflected a significant decrease in this novel
environment in the measures of ambulatory episodes, distance,
time, and counts (p < 0.01) (Figure 7A), indicating a reduction
in novelty-induced locomotor activity. Similar measurements of
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FIGURE 7 | Effects of a high-fat diet and CXCL12 on novelty-induced locomotor activity. (A) The intake of a HFD significantly decreased novelty-induced
locomotor activity during 15 min in a novel open field, as measured by ambulatory episodes, ambulatory distance, ambulatory time, and ambulatory counts. N = 16,
∗p < 0.01; and (B) Intracerebroventricular injection of CXCL12 significantly decreased novelty-induced locomotor activity during 15 min of exposure to the novel
open field, as measured by ambulatory episodes, ambulatory distance, ambulatory time, and ambulatory counts. N = 16, ∗p < 0.01.
locomotor activity for 15 min in a novel open field were then
recorded in rats injected in the third cerebral ventricle with saline
or CXCL12 at 50 ng. Analyses of these measures over the full
15 min also revealed a significant main effect of CXCL12 on
locomotor activity [F(1,56) = 16.74, p < 0.001), reflecting a
significant decrease in measures of ambulatory episodes, distance,
time, and counts (p < 0.01) (Figure 7B). These findings show
that CXCL12 is similar to a HFD in causing a decrease in
novelty-induced locomotor activity in an open field.
Central CXCL12 Injection Affects mRNA
Expression of Orexigenic Neuropeptides
This experiment examined whether central injection of CXCL12
can also stimulate the orexigenic neuropeptides believed to
be involved in mediating HFD ingestion and novelty-induced
locomotor activity. This chemokine was injected into the
third cerebral ventricle at 50 ng/3 µL, and its effects on
neuropeptide expression in the PVN, PFLH and ARC were
measured using qRT-PCR. In the PVN, CXCL12 compared to
saline vehicle caused a significant increase in mRNA levels of
ENK [t(14) == 2.62, p < 0.05] (Figure 8), similar to the effect
produced by a HFD (Figure 3). In contrast, CXCL12 injection
had no impact on GAL in the PVN [t(14) = 0.61, p = 0.55], on
OX [t(14)= 1.61, p= 0.13] and MCH [t(14)= 1.84, p= 0.10] in
the PFLH, or on NPY expression in the ARC (Figure 8). It also
had no impact on its own endogenous system, with mRNA levels
of CXCL12 and its receptors, CXCR4 and CXCR7, unaffected
in the PVN [F(2,14) = 0.40, p = 0.68], PFLH [F(2,14) = 0.22,
p = 0.80] and ARC [F(2,14) = 0.13, p = 0.88]. These results
demonstrate a specific stimulatory effect of CXCL12 on the
FIGURE 8 | CXCL12 effects on neuropeptide expression. Injection of
CXCL12 into the third ventricle caused a significant increase in the expression
of enkephalin (ENK) in the paraventricular nucleus (PVN), with no effect on
galanin (GAL). There was also no effect of CXCL12 on the expression of both
orexin (OX) and melanin-concentration hormone (MCH) in the perifornical
lateral hypothalamus (PFLH) and on the expression of neuropeptide Y (NPY) in
the arcuate nucleus (ARC). N = 24, †p < 0.05.
orexigenic peptide ENK in the PVN, where the CXCR4 receptors
are dense and stimulated along with this peptide by a HFD,
but they reveal no change in OX and MCH peptides in the
PFLH or NPY in the ARC where the CXCR4 receptors are not
detected.
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DISCUSSION
Although the classical function of chemokines is to induce
chemotaxis of immune cells, the current literature suggests a
causal relation to HFD intake and a possible role in mediating
diet-induced changes in neuronal function and behavior. The
results in this study reveal a positive relationship between the
CXCL12 system, orexigenic neuropeptides and dietary fat. The
ingestion of a HFD stimulates endogenous expression and levels
of CXCL12 and its receptors, CXCR4 and CXCR7, in the
hypothalamus, and these effects of a HFD occur in precisely
the same areas, the PVN and PFLH, where the fat-related
orexigenic neuropeptides are also increased by a HFD. This
positive relationship is in distinct contrast to our findings in
the ARC, where endogenous CXCL12 and its receptors are
sparse and unaffected by dietary fat and the neuropeptide NPY
is reduced by HFD intake. With central injection of CXCL12,
the results further demonstrate that this chemokine has similar
effects to a HFD on feeding-related behaviors, causing an increase
in caloric intake and a decrease in novelty-induced locomotor
activity. Like a HFD, CXCL12 also stimulates expression of the
orexigenic peptide ENK in the PVN, where a dense population
of CXCR4 receptors are found, but it has no impact on NPY
in the ARC where CXCR4 receptors are not detected. Whereas
the HFD stimulates the expression of CXCL12 and its receptors
in the PFLH where the orexigenic peptides, OX and MCH, are
also increased, this hypothalamic area differs from the PVN in
having undetectable protein levels of CXCR4 and showing no
effect of CXCL12 on the expression of these peptides. These
findings indicate that CXCL12 targets specifically the fat-sensitive
neuropeptide system in the PVN where it may have a role in
mediating the neurochemical and behavioral changes induced by
a HFD.
Region-Specific Effects of a HFD on
CXCL12, its Receptors and Orexigenic
Neuropeptides
While CXCL12 and its receptors have been identified in various
regions of the brain (Banisadr et al., 2003; Rostene et al.,
2011), their responsiveness in the brain to a fat-rich diet has
yet to be examined. Our results, in addition to confirming a
stimulatory effect of a HFD on the orexigenic neuropeptides
in the PVN and PFLH (Akabayashi et al., 1994; Elliott et al.,
2004; Chang et al., 2007; Gaysinskaya et al., 2007), reveal in
these same hypothalamic areas a simultaneous HFD-induced
increase in the expression of CXCL12, CXCR4 and CXCR7, and
in protein levels of CXCL12, with protein levels of CXCR4 also
increased in the PVN but not in the PFLH. Although CXCR7
failed to fluorescently label, the HFD-induced changes in its
expression, along with a similar change in expression and protein
levels of CXCR4, suggest that protein levels of CXCR7 may
also be increased. This close, positive relationship between this
CXCL12 system and the fat-stimulated neuropeptides found in
the PVN and PFLH is clearly site specific, and not evident in
the ARC. In this basal nucleus, the expression and levels of
endogenous CXCL12 and its receptors are found to be unaffected
by consumption of a HFD, and protein levels of CXCL12 and
CXCR4 are undetectable. Also, the orexigenic peptide NPY in this
nucleus is reduced by consumption of a HFD, as shown here and
in other studies (Giraudo et al., 1994; Wang et al., 1998, 2002),
and is positively associated with consumption of carbohydrate
rather than fat (Stanley et al., 1985; Jhanwar-Uniyal et al., 1993;
Wang et al., 1999). While several other neuropeptides related to
ingestive behavior exist in the hypothalamus, the results clearly
dissociate this chemokine system from the carbohydrate-related
neuropeptide, NPY, in the ARC, in distinct contrast to its positive
association with the fat-related neuropeptides in the PVN and
PFLH, as identified here.
Effect of Central CXCL12 Injection on
HFD Consumption
With a HFD known to promote excess consumption and
also shown to induce a low grade inflammation as confirmed
here by elevating circulating levels of CXCL12 during short-
term exposure, we examined whether the chemokine, CXCL12,
itself can also stimulate the intake of a HFD. Our results
show that an acute icv injection of CXCL12 increases HFD
consumption for the first 3 h after injection, with intake returning
to normal over a 24-h period after injection. Other studies,
showing this chemokine to affect expression and levels of
other neuromodulators such as MCH and vasopressin in the
hypothalamus (Guyon et al., 2005b, 2006; Callewaere et al., 2006)
and dopamine in the substantia nigra (Skrzydelski et al., 2007),
suggest a broad function of this chemokine on the brain. While
HFD itself induces an increase in CXCL12, the results here
reveal that an acute central dose of this chemokine similarly
effects ingestion, together with changes in orexigenic peptides as
described below.
Similar Effect of HFD and Central
CXCL12 Injection on Novelty-Induced
Locomotor Behavior
With the ingestion of a HFD known to reduce locomotor
behavior (Barzel et al., 2015; Wong et al., 2015) and our
results revealing molecular and behavioral effects of CXCL12
that are similar to those of a HFD, we investigated whether
this chemokine also affects locomotor behavior in a manner
similar to a HFD. The results of the present study support
this idea, confirming that intake of a HFD for 5 days reduces
locomotor activity in a novel open field, as previously shown
(Barzel et al., 2015; Wong et al., 2015), and also demonstrates that
central administration of CXCL12 similarly decreases novelty-
induced locomotor activity. Other studies have found CXCL12
in various brain regions to modulate locomotor behavior,
causing a reduction in activity with injection in the nucleus
accumbens (Trecki and Unterwald, 2009) and circling behavior
with injection in the substantia nigra (Skrzydelski et al., 2007),
once again providing evidence that this chemokine in the brain
may have broad effects on behavior. The new results reported
here support this idea, showing that CXCL12 in addition to
stimulating consummatory behavior also mimics the effects of a
HFD on novelty-induced locomotor activity
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Region-Specific Effects of Central
CXCL12 Injection on Orexigenic
Neuropeptides
With the HFD stimulating CXCL12 in conjunction with
neuropeptides in the PVN and PFLH and CXCL12 known to
affect the functioning of neurons (Guyon et al., 2005a, 2006;
Callewaere et al., 2006; Wu et al., 2009; Wang et al., 2011), it
is possible that this chemokine can modulate the hypothalamic
peptide neurons involved in ingestion and related behaviors. The
results of the present study are consistent with this possibility.
They demonstrate that central injection of CXCL12 has a distinct,
site-specific effect on ENK in the PVN, a nucleus with a dense
concentration of CXCR4 receptors and a neuropeptide that is
stimulated by HFD intake (Chang et al., 2007; Gaysinskaya
et al., 2007) and preferentially increases intake of a HFD (Robert
et al., 1989; Naleid et al., 2007). Thus, CXCL12 when elevated
by a HFD may have a role in mediating this diet’s effect on
ENK levels and ingestive behavior, and it may also act through
ENK to reduce novelty-induced locomotor activity, with central
or peripheral injection of this peptide or its analogs shown to
decrease locomotor activity (Bhargava, 1978; Szekely et al., 1980).
Whereas the ARC is clearly different from the PVN in providing
no evidence for a positive relationship between CXCL12, the
orexigenic peptide NPY, and dietary fat, the PFLH is similar
to the PVN in showing a stimulatory effect of a HFD on the
expression of CXCL12, its receptors, and the orexigenic peptides,
OX and MCH. However, it clearly differs markedly in revealing
no evidence for a role of CXCL12 in mediating the effects of a
HFD, with protein levels of CXCR4 undetectable in the PFLH
and central injection of CXCL12 having no effect on expression
of OX and MCH. While this evidence indicates that HFD-
induced stimulation of these neuropeptides in the PFLH occurs
independently of the CXCL12 system, other chemokines may
be involved. This is consistent with our analyses of GAL in the
PVN, a neuropeptide that is positively related to a HFD and
increased in a state of dietary obesity (Kyrkouli et al., 1990b;
Chen et al., 2005; Inouye et al., 2007) and, while unaffected by
CXCL12 as shown here, is stimulated by another chemokine,
CCL2 (Poon et al., 2014). Thus, multiple chemokine systems are
likely to function together in mediating the effects of a HFD on
the different orexigenic neuropeptides and the behaviors they
control.
CONCLUSION
This study is the first to reveal a site-specific, stimulatory
effect of short-term HFD intake on the CXCL12 chemokine
system and supports the idea that CXCL12 in the PVN, acting
through CXCR4, mimics the molecular and behavioral effects
of HFD. The results of this study raise several interesting
questions needing further investigation, for example, about the
nature of and differences between the CXCR4 and CXCR7
receptors, how inflammation itself might affect the function
of neurons, and whether the obese state associated with long-
term HFD consumption differentially affects this chemokine
system Whereas there are other chemokines possibly involved
in mediating the fat-induced changes in neuronal function and
behavior, CXCL12, which is known to be abundant in the
hypothalamus, is identified here to be similar to a HFD in
stimulating HFD intake, orexigenic neuropeptide expression, and
feeding-related behaviors.
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